FR2760193B1 - Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules - Google Patents
Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellulesInfo
- Publication number
- FR2760193B1 FR2760193B1 FR9702420A FR9702420A FR2760193B1 FR 2760193 B1 FR2760193 B1 FR 2760193B1 FR 9702420 A FR9702420 A FR 9702420A FR 9702420 A FR9702420 A FR 9702420A FR 2760193 B1 FR2760193 B1 FR 2760193B1
- Authority
- FR
- France
- Prior art keywords
- lipids
- transfection
- complexes
- cells
- active substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9702420A FR2760193B1 (fr) | 1997-02-28 | 1997-02-28 | Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules |
PCT/FR1998/000389 WO1998037916A1 (fr) | 1997-02-28 | 1998-02-27 | Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique |
US09/171,845 US6335199B1 (en) | 1997-02-28 | 1998-02-27 | Lipid compounds and compositions containing same used for the transfer of at least an active substance, in particular a polynucleotide, in a target cell and therapeutic use |
CA002252942A CA2252942A1 (fr) | 1997-02-28 | 1998-02-27 | Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique |
EP98912565A EP0948360A1 (fr) | 1997-02-28 | 1998-02-27 | Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique |
AU67352/98A AU727040B2 (en) | 1997-02-28 | 1998-02-27 | New lipid compounds and compositions containing them which can be used for the transfer of at least one active substance, in particular a polynucleotide, into a target cell and use in gene therapy |
JP10537387A JP2000510871A (ja) | 1997-02-28 | 1998-02-27 | 少なくとも一種の活性物質特にポリヌクレオチドを標的細胞中へ移送するのに使用できる新規脂質化合物およびこれを含む組成物、ならびに遺伝子治療における使用 |
US10/021,421 US20020151070A1 (en) | 1997-02-28 | 2001-12-19 | Lipid compounds and compositions containing them which can be used for the transfer of at least one active substance, in particular a polynucleotide, into a target cell and use in gene therapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9702420A FR2760193B1 (fr) | 1997-02-28 | 1997-02-28 | Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2760193A1 FR2760193A1 (fr) | 1998-09-04 |
FR2760193B1 true FR2760193B1 (fr) | 1999-05-28 |
Family
ID=9504295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9702420A Expired - Fee Related FR2760193B1 (fr) | 1997-02-28 | 1997-02-28 | Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules |
Country Status (7)
Country | Link |
---|---|
US (2) | US6335199B1 (fr) |
EP (1) | EP0948360A1 (fr) |
JP (1) | JP2000510871A (fr) |
AU (1) | AU727040B2 (fr) |
CA (1) | CA2252942A1 (fr) |
FR (1) | FR2760193B1 (fr) |
WO (1) | WO1998037916A1 (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030069173A1 (en) * | 1998-03-16 | 2003-04-10 | Life Technologies, Inc. | Peptide-enhanced transfections |
JP4854853B2 (ja) * | 1998-11-12 | 2012-01-18 | ライフ テクノロジーズ コーポレーション | トランスフェクション薬剤 |
US6184035B1 (en) * | 1998-11-18 | 2001-02-06 | California Institute Of Technology | Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells |
ATE312599T1 (de) * | 1999-10-01 | 2005-12-15 | Lipoxen Technologies Ltd | Impfstoffe zur oralen verwendung die liposomen sowie eine nukleinsäure enthalten |
WO2001042200A1 (fr) * | 1999-12-10 | 2001-06-14 | Genzyme Corporation | Amphiphiles cationiques pour administration intracellulaire de molecules therapeutiques |
US20020142304A1 (en) * | 2001-03-09 | 2002-10-03 | Anderson Daniel G. | Uses and methods of making microarrays of polymeric biomaterials |
GB0222824D0 (en) * | 2002-10-02 | 2002-11-06 | Moredun Res Inst | Bacteriophage-mediated immunisation II |
JP5777846B2 (ja) | 2005-06-15 | 2015-09-09 | マサチューセッツ インスティテュート オブ テクノロジー | アミン含有脂質およびその使用 |
US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
US8969353B2 (en) | 2008-11-07 | 2015-03-03 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
EA019538B1 (ru) * | 2009-04-30 | 2014-04-30 | Бактериефритт Ас | Композиция для стерилизации поверхностей |
ES2666559T3 (es) | 2009-12-01 | 2018-05-07 | Translate Bio, Inc. | Entrega del mrna para la aumentación de proteínas y enzimas en enfermedades genéticas humanas |
EP2609135A4 (fr) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | Poly(bêta-amino-alcools), leur préparation et utilisations de ceux-ci |
US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
DK3586861T3 (da) | 2011-06-08 | 2022-04-25 | Translate Bio Inc | Lipidnanopartikelsammensætninger og fremgangsmåder til mrna-indgivelse |
EP2859102A4 (fr) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | Polynucléotides résistant à la nucléase et leurs utilisations |
CA2884870C (fr) | 2012-08-13 | 2022-03-29 | Massachusetts Institute Of Technology | Lipidoides contenant des amines et leurs utilisations |
NZ751462A (en) | 2013-03-14 | 2021-07-30 | Shire Human Genetic Therapies | Cftr mrna compositions and related methods and uses |
EP2970955B1 (fr) | 2013-03-14 | 2018-11-14 | Translate Bio, Inc. | Procédés de purification d'arn messager |
WO2014179562A1 (fr) | 2013-05-01 | 2014-11-06 | Massachusetts Institute Of Technology | Dérivés de 1,3,5-triazinane-2,4,6-trione et leurs utilisations |
KR102096796B1 (ko) | 2013-10-22 | 2020-05-27 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna의 전달을 위한 지질 제형 |
EP3574923A1 (fr) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Thérapie d'arnm pour phénylcétonurie |
AU2014340092B2 (en) | 2013-10-22 | 2019-09-19 | Translate Bio, Inc. | mRNA therapy for Argininosuccinate Synthetase Deficiency |
EP3636742A1 (fr) | 2014-04-25 | 2020-04-15 | Translate Bio, Inc. | Procédés de purification d'arn messager |
AU2015266764B2 (en) | 2014-05-30 | 2019-11-07 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
JP6599373B2 (ja) | 2014-06-24 | 2019-10-30 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 核酸の送達のための立体化学的に濃縮した組成物 |
US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
WO2016011203A1 (fr) | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions comprenant des agrégats lipidiques et procédés d'administration efficace de molécules dans des cellules |
US11826423B2 (en) | 2016-11-16 | 2023-11-28 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
CA3054062A1 (fr) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Nouvel arnm cftr a codons optimises |
US11203629B2 (en) | 2017-04-22 | 2021-12-21 | Immunomic Therapeutics, Inc. | LAMP constructs |
AU2018263923B9 (en) | 2017-05-02 | 2024-09-19 | Immunomic Therapeutics, Inc. | LAMP (lysosomal associated membrane protein) constructs comprising cancer antigens |
WO2018213476A1 (fr) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
WO2019222281A1 (fr) | 2018-05-15 | 2019-11-21 | Immunomic Therapeutics, Inc | Constructions améliorées de lamp comprenant des allergènes |
CA3108544A1 (fr) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Procedes de purification d'arn messager |
MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
CA3153850A1 (fr) | 2019-10-18 | 2021-04-22 | Teri Heiland | Constructions ameliorees de lamp comprenant des antigenes du cancer |
CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
EP4176087A1 (fr) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Procédé de détermination de la réactivité à un traitement du cancer de la prostate |
EP4175721A1 (fr) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Néo-antigènes prostatiques et leurs utilisations |
EP4175664A2 (fr) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Néo-antigènes prostatiques et leurs utilisations |
CN119233982A (zh) | 2022-04-10 | 2024-12-31 | 免疫治疗有限公司 | 包含免疫应答增强基因的双顺反子lamp构建体及其使用方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
WO1996040726A1 (fr) | 1995-06-07 | 1996-12-19 | Genta Incorporated | Nouveaux lipides cationiques a base de carbamate |
TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
EP0869937A4 (fr) * | 1995-07-21 | 2004-07-21 | Promega Biosciences Inc | Nouveaux lipides cationiques a base d'amides |
DE19607686A1 (de) * | 1996-02-29 | 1997-09-04 | Chemicon Lab Gmbh | Neue metabolisierbare Lipopolyamine, deren Darstellung und Anwendung |
-
1997
- 1997-02-28 FR FR9702420A patent/FR2760193B1/fr not_active Expired - Fee Related
-
1998
- 1998-02-27 CA CA002252942A patent/CA2252942A1/fr not_active Abandoned
- 1998-02-27 JP JP10537387A patent/JP2000510871A/ja active Pending
- 1998-02-27 AU AU67352/98A patent/AU727040B2/en not_active Ceased
- 1998-02-27 EP EP98912565A patent/EP0948360A1/fr not_active Withdrawn
- 1998-02-27 US US09/171,845 patent/US6335199B1/en not_active Expired - Fee Related
- 1998-02-27 WO PCT/FR1998/000389 patent/WO1998037916A1/fr not_active Application Discontinuation
-
2001
- 2001-12-19 US US10/021,421 patent/US20020151070A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1998037916A1 (fr) | 1998-09-03 |
AU727040B2 (en) | 2000-11-30 |
JP2000510871A (ja) | 2000-08-22 |
EP0948360A1 (fr) | 1999-10-13 |
US20020151070A1 (en) | 2002-10-17 |
CA2252942A1 (fr) | 1998-09-03 |
AU6735298A (en) | 1998-09-18 |
FR2760193A1 (fr) | 1998-09-04 |
US6335199B1 (en) | 2002-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2760193B1 (fr) | Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules | |
FI973320L (fi) | Kiinteitä aktiiviainetta sisältäviä valmisteita | |
PL341737A1 (en) | Double capsule for administering active substances in multiple-dug therapies | |
FI972514A0 (fi) | Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi | |
PT869126E (pt) | Derivados de ditiolano, sua preparacao e seus efeitos terapeuticos | |
ID26237A (id) | Pengantaran zat aktif teraerosolisasi | |
PL327767A1 (en) | Drugs containing known auxiliary substances and an active substance | |
DE60003938D1 (de) | Wirkstoffe in hydrogel-mikroperlen | |
DE69818443D1 (de) | Aktives flüssigkeitslager | |
DE69821940D1 (de) | Landwirtschaftlich aktive inhaltsstoffe enthaltende mikropartikel | |
PT1069890E (pt) | Incorporacao de substancias activas em matrizes veiculares | |
HU9800075D0 (en) | Nucleic acid construct for expressing active substances wich can be activated by proteases, and preparation and use | |
NO994438L (no) | Terapeutisk aktive diarylpropylaminer samt fremstilling og anvendelse derav | |
DE69710335D1 (de) | Wirkstoffabgebende zusatzmittel und diese enthaltende reinigungsmittelstücke | |
SI1051174T1 (sl) | Gastroprotektirane omeprazolne mikrogranule, postopek za pridobivanje le-teh in farmacevtski pripravki | |
IS5504A (is) | Samsetning virk við meðhöndlun á getuleysi | |
DK0927222T3 (da) | Termoplastiske polyurethaner indeholdende virksomme stoffer | |
DE69919490D1 (de) | Puder mit fettlöslichem wirkstoff | |
PT1083790E (pt) | Formulacoes de retardacao para substancias activas fitofarmaceuticas | |
DE69627880D1 (de) | Diltiazemhaltige mikrogranulate mit verzögerter wirkstoffabgabe | |
PL351988A1 (en) | Synthetic gene for expressing active retroviral protein in eukaryotes | |
PT1221845E (pt) | Combinacoes de substancias activas com caracteristicas insecticidas e acaricidas | |
DZ2560A1 (fr) | Préparations pharmaceutiques de cilansétrone stabilisées contre la racémisation. | |
ATE228575T1 (de) | Wirkstoffkombinationen | |
DK0922703T3 (da) | Substituerede heterocykliske benzocycloalkener og disses anvendelse som analgetisk virksomme stoffer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |